Theralase Technologies Inc
XTSX:TLT
Intrinsic Value
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. [ Read More ]
The intrinsic value of one
TLT
stock under the Base Case scenario is
0.57
CAD.
Compared to the current market price of 0.165 CAD,
Theralase Technologies Inc
is
Undervalued by 71%.
Theralase Technologies Inc's market capitalization is 37.7m CAD.
TLT stock price is 0.165 CAD.
TLT stock price (0.165 CAD) is 71% less than its Intrinsic Value (0.57 CAD).
TLT stock price (0.165 CAD) is 48% less than its Relative Value (0.316 CAD). Open Relative Valuation
TLT has upside potential of 395% compared to the average analyst price target.
Open Wall St Estimates
TLT's Revenue has dropped by 6% over the past 12 months.
TLT's Revenue has been growing by 5% per year for the last 3 years.
TLT's short-term assets (1m CAD) exceed its short-term liabilties (1m CAD).
TLT has negative Net Debt. This means that the company has more cash and short-term investments (318k CAD) than debt (294k CAD).
TLT's ROE (Return on Equity) has significantly decreased in the last 3 years from -47% to -183%, and is approaching profitability.
TLT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -247% to -207%, and is approaching profitability.
TLT has positive Gross Profit for the last twelve months.
TLT has negative Operating Income for the last twelve months.
TLT has negative Net Income for the last twelve months.
TLT's ROE (Return on Equity) for the past 12 months is negative and is equal to -183%.
TLT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -207%.
TLT's long-term assets (3m CAD) exceed its long-term liabilties (1m CAD).
TLT's Revenue is forecast to grow at a rate of 222% per year over the next 3 years.
TLT has negative Free Cash Flow for the last twelve months.
TLT's D/E (Debt to Equity) is very low and is equal to 0.15.
TLT has negative three-year average ROE (Return on Equity): -111%. The company is not efficient at transforming stockholders' equity into net income.
TLT has negative three-year average ROIC (Return on Invested Capital): -267%. The company is not efficient at using invested capital to generate operating income.
TLT's Altman Z-Score is very low and is equal to -10.63.
Valuation Backtest
Theralase Technologies Inc
Run backtest to discover the historical profit from buying and selling
TLT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Theralase Technologies Inc
Balance Sheet Decomposition
Theralase Technologies Inc
| Current Assets | 1.5m |
| Cash & Short-Term Investments | 317.6k |
| Receivables | 324.9k |
| Other Current Assets | 856.4k |
| Non-Current Assets | 1.8m |
| Long-Term Investments | 920k |
| PP&E | 857.9k |
| Current Liabilities | 1.1m |
| Accounts Payable | 682k |
| Accrued Liabilities | 302.5k |
| Other Current Liabilities | 93k |
| Non-Current Liabilities | 293.9k |
| Long-Term Debt | 293.9k |
| Other Non-Current Liabilities | -10 |
Earnings Waterfall
Theralase Technologies Inc
|
Revenue
|
1.1m
CAD
|
|
Cost of Revenue
|
-508.2k
CAD
|
|
Gross Profit
|
562.1k
CAD
|
|
Operating Expenses
|
-5.2m
CAD
|
|
Operating Income
|
-4.6m
CAD
|
|
Other Expenses
|
23.4k
CAD
|
|
Net Income
|
-4.6m
CAD
|
Free Cash Flow Analysis
Theralase Technologies Inc
TLT Profitability Score
Profitability Due Diligence
Theralase Technologies Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Theralase Technologies Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
TLT Solvency Score
Solvency Due Diligence
Theralase Technologies Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Theralase Technologies Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TLT Price Targets Summary
Theralase Technologies Inc
According to Wall Street analysts, the average 1-year price target for
TLT
is 0.816 CAD
with a low forecast of 0.808 CAD and a high forecast of 0.84 CAD.
Shareholder Return
TLT Price
Theralase Technologies Inc
| Average Annual Return | 0.64% |
| Standard Deviation of Annual Returns | 61.21% |
| Max Drawdown | -75% |
| Market Capitalization | 37.7m CAD |
| Shares Outstanding | 221 303 000 |
| Percentage of Shares Shorted | 0.01% |
Company Profile
Theralase Technologies Inc
Country
Industry
Market Cap
Dividend Yield
Description
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
Contact
IPO
Employees
Officers
The intrinsic value of one
TLT
stock under the Base Case scenario is
0.57
CAD.
Compared to the current market price of 0.165 CAD,
Theralase Technologies Inc
is
Undervalued by 71%.
You don't have any saved screeners yet
